The FDA’s recent move to modernize evidence standards marks a turning point in how drug value will be judged, priced and compared globally, with direct consequences for how pharmaceutical companies operate internally.

If evidence is becoming the currency of value, pharmaceutical leaders must stop treating it as a downstream exercise and start redesigning how assets are evaluated, developed and priced across the enterprise.